Overview

CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if CLONICEL (clonidine HCl sustained release) is a safe and effective add-on to psychostimulant therapy in children and adolescents with attention deficit hyperactivity disorder (ADHD).
Phase:
Phase 3
Details
Lead Sponsor:
Addrenex Pharmaceuticals, Inc.
Treatments:
Clonidine